Richard I. Fisher

Richard I. Fisher is among the architects of modern lymphoma therapy, having led or co-designed landmark cooperative group trials that established CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and subsequently R-CHOP as the global standard of care for aggressive non-Hodgkin lymphoma. His decades of work through the Southwest Oncology Group (SWOG), ECOG, and the national Intergroup framework produced the definitive studies that rationalized treatment selection across histologic subtypes and risk groups. Fisher was the principal investigator of the pivotal Intergroup NHL trial that compared third-generation chemotherapy regimens (m-BACOD, ProMACE-CytaBOM, MACOP-B) against CHOP, demonstrating equivalent efficacy with far lower toxicity—cementing CHOP as the standard backbone against which all subsequent regimens would be measured. When rituximab became available, he contributed to the framework for evaluating rituximab-chemotherapy combinations in both indolent and aggressive lymphomas. He has also made major contributions to understanding the role of dose intensity, salvage regimens, and high-dose therapy followed by autologous stem cell rescue in relapsed/refractory settings. Fisher has served in leadership roles at multiple NCI-designated cancer centers, including the University of Rochester and Fox Chase Cancer Center. His mentorship, editorial service, and guideline contributions have shaped a generation of lymphoma specialists. He continues to contribute to clinical and translational research on novel agents in aggressive B-cell lymphomas, including CAR-T cell therapy and bispecific antibody approaches in the relapsed setting.